Wall Street analysts expect VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) to announce sales of $130,000.00 for the current quarter, according to Zacks. Two analysts have made estimates for VBI Vaccines’ earnings. The highest sales estimate is $160,000.00 and the lowest is $100,000.00. VBI Vaccines reported sales of $300,000.00 in the same quarter last year, which would suggest a negative year-over-year growth rate of 56.7%. The business is expected to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that VBI Vaccines will report full-year sales of $5.74 million for the current fiscal year, with estimates ranging from $4.00 million to $8.01 million. For the next fiscal year, analysts forecast that the company will report sales of $29.03 million, with estimates ranging from $20.60 million to $43.08 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for VBI Vaccines.
VBI Vaccines (NASDAQ:VBIV – Get Rating) last released its earnings results on Monday, March 7th. The biopharmaceutical company reported ($0.07) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.07). VBI Vaccines had a negative return on equity of 42.79% and a negative net margin of 11,054.36%. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.14 million.
VBI Vaccines stock traded up $0.09 during mid-day trading on Wednesday, hitting $1.67. The company had a trading volume of 1,420,723 shares, compared to its average volume of 2,297,321. The company has a current ratio of 4.00, a quick ratio of 3.92 and a debt-to-equity ratio of 0.20. The stock’s 50 day moving average price is $1.54 and its two-hundred day moving average price is $2.23. VBI Vaccines has a 12 month low of $1.21 and a 12 month high of $4.31. The company has a market capitalization of $429.70 million, a PE ratio of -6.19 and a beta of 1.97.
A number of institutional investors have recently bought and sold shares of VBIV. PNC Financial Services Group Inc. increased its position in VBI Vaccines by 433.0% during the third quarter. PNC Financial Services Group Inc. now owns 8,448 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 6,863 shares during the last quarter. Wealth Alliance Advisory Group LLC purchased a new stake in VBI Vaccines during the fourth quarter valued at $28,000. WINTON GROUP Ltd purchased a new stake in VBI Vaccines during the third quarter valued at $31,000. Mackenzie Financial Corp purchased a new stake in VBI Vaccines during the third quarter valued at $34,000. Finally, Point72 Hong Kong Ltd purchased a new stake in VBI Vaccines during the fourth quarter valued at $43,000. Institutional investors own 43.61% of the company’s stock.
About VBI Vaccines (Get Rating)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Insiders Are Selling Palo Alto Networks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.